Enfuvirtide

Mechanism

The first peptide-based antiviral drug — a 36-amino acid peptide that physically blocks HIV from fusing with and entering human immune cells. It works like a molecular doorstop, jamming the viral fusion machinery. Reserved for treatment-experienced HIV patients because it requires twice-daily subcutaneous injections and causes injection site reactions in nearly all patients.

Effects

## Detailed Effects — Enfuvirtide ### Immune System / Antiviral [Tier 1] - Blocks HIV-1 entry at the membrane fusion step by binding to the HR1 domain of gp41, preventing the six-helix bundle formation required for viral-host cell membrane fusion. - Active against HIV-1 only (not HIV-2) — the gp41 HR2 sequence from which enfuvirtide is derived is HIV-1 specific. - Effective against multi-drug resistant HIV-1 strains that are resistant to NRTIs, NNRTIs, and PIs, since the mechanism of action is entirely distinct. - In combination with optimized background regimen: additional 0.9 log10 viral load reduction vs background regimen alone at 24 weeks (TORO 1 & 2 trials). - CD4 count recovery: additional 36-71 cells/mm3 vs control at 48 weeks in treatment-experienced patients. ### Injection Site Reactions [Tier 1] - Injection site reactions (ISRs) occur in ~98% of patients — nodules, erythema, induration, pain, ecchymosis. - ISRs are the primary tolerability limitation. Most (85%) are mild-moderate, but ~9% of patients discontinue due to ISRs. - Subcutaneous nodules may persist for weeks; rotating injection sites is essential. ### Systemic Effects [Tier 1] - Hypersensitivity reactions (<1%) including rash, fever, nausea, hypotension — rechallenge is contraindicated after hypersensitivity. - Increased rate of bacterial pneumonia observed in clinical trials (relative risk ~2x) — mechanism unclear, may relate to immunomodulatory effects or patient population. - Eosinophilia reported in some patients. - No significant hepatic, renal, or metabolic toxicity — not a CYP substrate.

Practitioner Guide

## Practitioner Guide — Enfuvirtide ### Current Clinical Role - **Salvage therapy only**: enfuvirtide is reserved for treatment-experienced patients with multi-drug resistant HIV-1 who have limited options with oral regimens. - With the advent of newer agents (dolutegravir, bictegravir, cabotegravir-rilpivirine LA, lenacapavir, ibalizumab, fostemsavir), enfuvirtide use has declined dramatically. - Still occasionally used when all other options are exhausted — its unique mechanism means no cross-resistance with any oral ARV class. ### Dosing & Administration - **Dose**: 90 mg (1 mL reconstituted) subcutaneous injection BID (every 12 hours). - **Reconstitution**: Each vial contains 108 mg lyophilized powder. Add 1.1 mL sterile water for injection (supplied). Allow to dissolve — may take up to 45 minutes. DO NOT shake — gently roll the vial. Final concentration 90 mg/mL. - **Injection sites**: Upper arm, anterior thigh, or abdomen. Rotate sites. Avoid injecting into moles, scar tissue, bruises, or near the navel. - **Injection site management**: Apply warm compresses before injection to reduce pain. Massage injection site gently after administration. Cold packs post-injection can reduce inflammation. ### Patient Training Protocol - Patients must be trained on reconstitution, injection technique, and injection site rotation. - Provide biohazard sharps containers and a clear injection site rotation chart. - Many clinics assign a dedicated nurse for initial training sessions. - Reconstituted solution is clear and colorless — discard if particulate or discolored. ### Storage & Stability - Unreconstituted vials: store at room temperature (25°C). Can also refrigerate. - Reconstituted solution: refrigerate (2-8°C), use within 24 hours. Do NOT freeze. - The convenience kit includes vials, diluent, syringes, alcohol wipes, and sharps container. ### Cost & Access Considerations - Enfuvirtide remains extremely expensive (~$25,000-36,000/year) due to complex solid-phase peptide synthesis (36 amino acids). - Most patients access through insurance with specialty pharmacy support or manufacturer patient assistance programs (Genentech/Roche). - BID injection requirement and ISRs are major adherence barriers. ### Monitoring - Viral load and CD4 count at baseline, 4 weeks, then every 3 months. - Monitor injection sites at each visit — document ISR severity, advise on rotation. - Watch for signs of hypersensitivity (rash, fever, chills, hypotension) — discontinue permanently if suspected. - Monitor for signs of pneumonia (increased rate observed in clinical trials).

Evidence

• Transdermal delivery of enfuvirtide using dissolving microneedles integrated with novel insertion and removal indicator.

  Li H et al. (2025) — Journal of Controlled Release — PMID: 40532764

  A dissolving microneedle patch platform delivered enfuvirtide transdermally in rats with rapid indicator-guided dissolution, achieved higher and earlier Cmax versus a comparator patch design, and was well tolerated in vivo, suggesting a potential route to reduce injection-site burden associated with subcutaneous enfuvirtide.

  emerging

• Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

  Lalezari JP et al. (2003) — N Engl J Med — PMID: 12637625

  In TORO 1, adding enfuvirtide to an optimized antiretroviral background regimen produced larger 24-week reductions in HIV-1 RNA than control (-1.696 vs -0.764 log10 copies/mL, P<0.001) and greater CD4 increase (76 vs 32 cells/mm3), with frequent injection-site reactions and more pneumonia cases observed.

  strong

Research Summary

## Research Summary — Enfuvirtide ### Tier 1: Randomized Controlled Trials - **TORO 1 (Lalezari et al., NEJM 2003, n=501)**: Enfuvirtide + optimized background regimen (OBR) vs OBR alone in treatment-experienced patients. Enfuvirtide arm: 37% achieved <400 copies/mL at 24 weeks vs 16% in control. Additional 0.9 log10 viral load reduction. - **TORO 2 (Lazzarin et al., NEJM 2003, n=504)**: Confirmatory trial. 28% achieved <400 copies/mL vs 12% control at 24 weeks. Consistent benefit across all subgroups. - **48-week TORO pooled analysis**: Durable virologic suppression maintained. CD4 gains of 71 cells/mm3 vs 35 cells/mm3 in control. ### Tier 2: Systematic Reviews & Meta-Analyses - Defined a new class (fusion inhibitors) and demonstrated proof-of-concept for entry inhibition as an antiretroviral strategy. - Reviews consistently note that enfuvirtide's clinical role has been largely supplanted by newer oral agents and long-acting injectables (cabotegravir-rilpivirine, lenacapavir). - Pharmacoeconomic analyses show poor cost-effectiveness vs newer agents given BID injection burden and high cost. ### Tier 3: Case Reports & Practitioner Protocols - Case reports of successful use in heavily treatment-experienced patients with resistance to 3+ drug classes. - Anecdotal reports of off-label continuous subcutaneous infusion via pump to reduce injection burden — limited data. - Practitioner experience: the BID injection schedule and nearly universal ISRs make long-term adherence very difficult. ### Gaps - No head-to-head trials against newer salvage agents (ibalizumab, fostemsavir, lenacapavir). - Optimal ISR management strategies not well studied in RCTs. - No pediatric pharmacokinetic data below age 6. ### Active Trials - Minimal ongoing trial activity as enfuvirtide is increasingly obsolete in clinical practice. Most HIV pipeline research focuses on long-acting agents and broadly neutralizing antibodies.